



October 5, 2007

Peregrine Pharmaceuticals to Present at BIO Investor Forum 2007

- Presentation to Be Webcast Live On Company's Website -

TUSTIN, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the BIO Investor Forum 2007 on Wednesday, October 10, 2007 at 3:45 pm PT (6:45 pm ET). The conference will be held at the Palace Hotel in San Francisco.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section of Peregrine's website at <http://www.peregrineinc.com>. A replay will be available on the Peregrine website and archived for approximately 30 days.

For more information about this conference, please visit: <http://investorforum.bio.org/opencms/bif/2007/>

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara[®]. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (<http://www.avidbio.com>), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at <http://www.peregrineinc.com>.

SOURCE Peregrine Pharmaceuticals, Inc.

CONTACT: Investors, GendeLLindheim BioCom Partners, 1-800-987-8256, info@peregrineinc.com, for Peregrine; or Media, Jennifer Anderson, +1-212-918-4642, for Peregrine

Web site: <http://www.peregrineinc.com>